GGrantIndex
← Leaderboards

Jennifer Hartt Elisseeff

Johns Hopkins University

$18,978,528
Attributed
$23,170,540
Total exposure
13
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.1M · FY200525
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$28,636,207 · 14

By mechanism

R01$15,634,032 · 8
U54$6,849,175 · 3
DP1$5,731,250 · 1
R21$408,750 · 1
R13$13,000 · 1

Top collaborators

Most similar at Johns Hopkins University

Same institution · by research overlap

Others in their field

Top investigators on “Tissues

Research focus

TissuesCellsIn VivoResponseSenescenceBiocompatible MaterialsDesignIn VitroBiologicalScaffoldTissue EngineeringImmune SystemRepairedAgingBaseSingle-Cell Rna SequencingResearch PersonnelTechnologyCell CommunicationStructureProgramsImmuneData SetExtracellular Matrix

Grant awards (53)

JHU-Mayo-NIA Murine Senescence Mapping Program (JMN-MSMP)$1,316,448
U54 · FY2025 · AG · contact PI
Role of senescent cells in uterine fibroid pathogenesis$791,630
R01 · FY2025 · HD
Senescence in the Foreign Body Response Across Lifespan$647,300
R01 · FY2025 · AG · contact PI
Administrative Core$200,000
U54 · FY2025 · AG · contact PI
JHU-Mayo-NIA Murine Senescence Mapping Program (JMN-MSMP)$200,000
U54 · FY2025 · AG · contact PI
Administrative Core$91,636
U54 · FY2025 · AG · contact PI
JHU-Mayo-NIA Murine Senescence Mapping Program (JMN-MSMP)$1,316,448
U54 · FY2024 · AG · contact PI
Role of senescent cells in uterine fibroid pathogenesis$803,402
R01 · FY2024 · HD
Senescence in the Foreign Body Response Across Lifespan$660,510
R01 · FY2024 · AG · contact PI
Administrative Core$312,684
U54 · FY2024 · AG · contact PI
JHU-Mayo-NIA Murine Senescence Mapping Program (JMN-MSMP)$1,316,448
U54 · FY2023 · AG · contact PI
Biomaterials-directed regenerative immunotherapies$1,146,250
DP1 · FY2023 · AR · contact PI
Role of senescent cells in uterine fibroid pathogenesis$818,748
R01 · FY2023 · HD
Administrative Core$690,827
U54 · FY2023 · AG · contact PI
Single cell characterization of the biomaterial immune and stromal response$612,340
R01 · FY2023 · EB · contact PI
Develop BCL-xL proteolysis targeting chimeras as safer and better senolytics$501,347
R01 · FY2023 · AG
JHU-Mayo-NIA Murine Senescence Mapping Program (JMN-MSMP)$1,316,323
U54 · FY2022 · AG · contact PI
Biomaterials-directed regenerative immunotherapies$1,146,250
DP1 · FY2022 · AR · contact PI
Single cell characterization of the biomaterial immune and stromal response$612,340
R01 · FY2022 · EB · contact PI
Develop BCL-xL proteolysis targeting chimeras as safer and better senolytics$503,572
R01 · FY2022 · AG
Administrative Core$88,361
U54 · FY2022 · AG · contact PI
Biomaterials-directed regenerative immunotherapies$1,146,250
DP1 · FY2021 · AR · contact PI
Single cell characterization of the biomaterial immune and stromal response$606,585
R01 · FY2021 · EB · contact PI
Develop BCL-xL proteolysis targeting chimeras as safer and better senolytics$505,755
R01 · FY2021 · AG
Statistical optimization of self-assembled biosynthetic cornea implants$381,236
R01 · FY2021 · EY · contact PI
Biomaterials-directed regenerative immunotherapies$1,146,250
DP1 · FY2020 · AR · contact PI
Single cell characterization of the biomaterial immune and stromal response$618,965
R01 · FY2020 · EB · contact PI
Develop BCL-xL proteolysis targeting chimeras as safer and better senolytics$507,895
R01 · FY2020 · AG
Statistical optimization of self-assembled biosynthetic cornea implants$392,537
R01 · FY2020 · EY · contact PI
Biomaterials-directed regenerative immunotherapies$1,146,250
DP1 · FY2019 · AR · contact PI
Develop BCL-xL proteolysis targeting chimeras as safer and better senolytics$560,435
R01 · FY2019 · AG
Statistical optimization of self-assembled biosynthetic cornea implants$503,355
R01 · FY2019 · EY · contact PI
Statistical optimization of self-assembled biosynthetic cornea implants$505,834
R01 · FY2018 · EY · contact PI
2014 TERMIS-Americas Conference Opening Symposium$13,000
R13 · FY2015 · EB · contact PI
Glucosamine and Novel Anolgs for Cartilage Regeneration$446,662
R01 · FY2013 · AR · contact PI
Glucosamine and Novel Anolgs for Cartilage Regeneration$407,271
R01 · FY2012 · AR · contact PI
Glucosamine and Novel Anolgs for Cartilage Regeneration$51,893
R01 · FY2012 · AR · contact PI
Glucosamine and Novel Anolgs for Cartilage Regeneration$407,271
R01 · FY2011 · AR · contact PI
Glucosamine and Novel Anolgs for Cartilage Regeneration$413,881
R01 · FY2010 · AR · contact PI
Tissue Engineering in Congenital Craniofacial Defects$381,324
R01 · FY2009 · DE · contact PI
Tissue Engineering in Congenital Craniofacial Defects$324,560
R01 · FY2008 · DE · contact PI
Synthesis amd Mechanism of Polyglucosamine for Cartilage Tissue Engineering$271,571
R01 · FY2008 · AR · contact PI
Engineering and Integration of Osteochondral Tissue$271,195
R01 · FY2008 · EB · contact PI
Tissue Engineering in Congenital Craniofacial Defects$50,414
R01 · FY2008 · DE · contact PI
Tissue Engineering in Congenital Craniofacial Defects$327,737
R01 · FY2007 · DE · contact PI
Engineering and Integration of Osteochondral Tissue$276,490
R01 · FY2007 · EB · contact PI
Synthesis amd Mechanism of Polyglucosamine for Cartilage Tissue Engineering$269,017
R01 · FY2007 · AR · contact PI
Tissue Engineering in Congenital Craniofacial Defects$350,742
R01 · FY2006 · DE · contact PI
Engineering and Integration of Osteochondral Tissue$284,000
R01 · FY2006 · EB · contact PI
Synthesis amd Mechanism of Polyglucosamine for Cartilage Tissue Engineering$276,447
R01 · FY2006 · AR · contact PI
Engineering and Integration of Osteochondral Tissue$289,771
R01 · FY2005 · EB
Targeted Integration of Tissue Engineered Cartilage$204,375
R21 · FY2004 · EB
Targeted Integration of Tissue Engineered Cartilage$204,375
R21 · FY2003 · EB